代理机构 |
Birch, Stewart, Kolasch & Birch, LLP |
代理人 |
Birch, Stewart, Kolasch & Birch, LLP |
主权项 |
1. A pharmaceutical jelly composition formulated for oral administration, said pharmaceutical jelly composition comprising:
a first pharmaceutical component comprising icosapentaenoic acid or an ethyl ester thereof; a second pharmaceutical component comprising an antihyperlipidemic agent selected from the group consisting of statin drugs (HMG-CoA reductase inhibitors), fibrates, squalene synthase inhibitor, and cholesterol absorption inhibitor; from 0.05 to 10% by weight, based upon the total weight of the jelly composition, of an emulsifying agent which is at least one member selected from the group consisting of polyoxyethylene polyoxypropylene glycol, sucrose fatty acid ester, lecithin, polyglycerin fatty acid ester, glycerin fatty acid ester, sorbitan fatty acid ester, propylene glycol fatty acid ester, and a saturated fatty acid containing 12 to 22 carbon atoms; a gelling agent which is at least one member selected from the group consisting of carrageenan and locust bean gum; and from 0.5 to 5% by weight, based upon the total weight of the jelly composition, of a syneresis inhibitor selected from the group consisting of carmellose sodium, pullulan, hydroxypropyl methylcellulose, hydroxypropyl cellulose, and crystalline cellulose, wherein said pharmaceutical jelly composition has a jelly strength of 50 to 250gf/cm2 and wherein said pharmaceutical jelly composition has a release ratio of higher than 50% of icosapentaenoic acid or an ethyl ester thereof, into a test solution in a beaker containing 2000nylon beads having a diameter of 6.4 mm, 30 minutes after mixing the jelly composition into the test solution and stirring at a temperature of 37° C. with a paddle rotation rate of 25, said test solution being composed of 160 mL of an artificial gastric juice comprising an aqueous solution containing 115 mmol/L of sodium chloride and 35 mmol/L of potassium chloride adjusted with hydrochloric acid to a pH of 2.5. |